After the initial success in melanoma, anti-CTLA-4 antibodies like ipilimumab were tested in solid tumors such as breast cancer with limited efficacy [83], though it has been recently approved for the treatment of lung cancer in combination with the anti-PD1 antibody nivolumab in advanced NSCLC [84]. The gene discussed is CTLA4; the disease is melanoma.